AstraZeneca said it will be buying 50,000 software licences for Acrobat, initially for its UK, US and Swedish operations. The firm will use the software to track amendments to data from drug trials and store data in-line with regulatory requirements.
AstraZeneca said staff in 108 countries will create, share, review and archive files in Portable Document Format (PDF).
The PDFs will be accessed via AstraZeneca's existing Documentum system. The company said using Acrobat will enable smoother external communications with regulatory agencies, suppliers and distributors.
Thomas Ehrnstrohm, director of global IS strategy, said, "Acrobat enables simultaneous, shared access to files and will make it far easier to track documents as they progress through the lengthy regulatory review process.
"With most new drugs subject to a complex development cycle, it is critical for AstraZeneca to maintain tight control over all documentation. Acrobat will also make it far easier to manage external communications by allowing us to maintain precise, secure records of correspondence with regulatory bodies, partners, customers and patients."